Phase 2 N=98 Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Lymphoma
Primary: Progression Free Survival — 79 percentage of patients progression free
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Study of D-Methadone in Patients With Chronic Pain
Pain · Bladder Cancer · Breast Cancer
Primary: Number Who Reached a Safe Dose — 8 participants
Phase 2 N=40 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Phase 2 N=182 Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
Diabetic Neuropathy, Painful
Primary: Time to Efficacy Failure (TTEF) - Primary Responders — NA; NA Days
Phase 2 N=27 Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
MELAS Syndrome
Primary: Mean Change in Cerebral Lactate Concentration (as Measured by Magnetic Resonance Spectroscopy) — -0.09; 0.16; -0.49 IU
Phase 2 N=97 Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Bladder Cancer
Primary: Treatment Completion Rate — 67; 53 percentage of participants
Phase 2 N=46 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
Cancer of Head · Cancer of Head and Neck · Cancer of Neck
Primary: Probability of Progression-free Survival (PFS) at 2 Years — 70 percentage of participants
Phase 2 N=18 Anastrozole in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Plasma Estradiol (E2) Level — -40; -4 % change from baseline
Phase 2 N=56 A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Locally Recurrent · Metastatic Breast Cancer ( HER2 Negative)
Primary: Objective Response Rate (ORR) — 28.6 Percentage of participants
Phase 2 N=42 Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Phase 2 N=21 EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)
Head and Neck Cancer
Primary: Participants With Mucositis and Hematological Toxicities With the Addition of Radioprotector Amifostine — 16 participants
Phase 2 N=40 Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
Prostate Cancer
Primary: Number of Participants Progression Free at 1 Year — 13 participants
Phase 2 N=566 Aclidinium/Formoterol Fixed Combination Dose Finding Study
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr — 0.170; 0.219; 0.230; 0.075 Liters — p=<0.0001
Phase 2 N=68 A Study of Ketamine in Patients With Treatment-resistant Depression
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15 — 35.6; 33.3; 36.8; 35.4 Units on a scale — p=< 0.001
Phase 2 N=76 A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression
Hepatitis B, Chronic
Primary: Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48) — 59.13 percent change